QYNAPSE

Founded in 2015, QYNAPSE is a medical technology company, a spin-off from the CATI consortium of neuroimaging research laboratories in France. QYNAPSE develops and markets solutions maximizing the potential of quantitative imaging and artificial intelligence to optimize diagnosis, prognosis and monitoring of patients with neurological diseases. QYNAPSE is already marketing its QyScore® software for the automated quantification of imaging markers for clinical routine and clinical trials worldwide and is also launching QyPredict®, an AI prediction technology for better targeted patient selection in clinical trials. The company is headquartered in France, in the United States and in Canada.